
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restor... Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0251 | 2.5484820794 | 0.9849 | 1.03 | 0.90695 | 101017 | 0.97681205 | CS |
4 | -0.09 | -8.18181818182 | 1.1 | 1.235 | 0.90695 | 108509 | 1.06348815 | CS |
12 | 0.065 | 6.87830687831 | 0.945 | 1.49 | 0.69215 | 180187 | 1.07566272 | CS |
26 | -0.08 | -7.33944954128 | 1.09 | 1.94 | 0.69215 | 166087 | 1.19860172 | CS |
52 | -3.34 | -76.7816091954 | 4.35 | 4.99 | 0.69215 | 335335 | 2.07206643 | CS |
156 | -3.05 | -75.1231527094 | 4.06 | 11.76 | 0.69215 | 325142 | 4.68374677 | CS |
260 | -17.6 | -94.572810317 | 18.61 | 60.5162 | 0.69215 | 283549 | 8.73005131 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions